home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Edwards Lifesciences (NY:EW)

84.28 -1.50 (-1.75%)

Streaming Delayed Price Updated: 11:45 AM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

The Latest Analyst Ratings for Edwards Lifesciences ↗

April 24, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 5 Years ↗

April 24, 2023

Via Benzinga

3 No-Brainer Medical Device Stocks to Buy Right Now ↗

April 06, 2023

These companies have consistently delivered revenue and EPS gains.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023 ↗

March 29, 2023

Via Benzinga

The Latest Analyst Ratings for Edwards Lifesciences ↗

March 29, 2023

Via Benzinga

Looking Into Edwards Lifesciences's Recent Short Interest ↗

March 15, 2023

Via Benzinga

Expert Ratings for Edwards Lifesciences ↗

March 08, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗

March 08, 2023

Via Benzinga

Interview With David Rolfe of Wedgewood Partners ↗

February 17, 2023

Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe.

Via The Motley Fool

Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 4 ↗

February 04, 2023

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Jan. 30 through Feb. 3.

Via Talk Markets

Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views ↗

January 31, 2023

The company expects full-year sales to grow 9%-12% in constant currency.

Via Investor's Business Daily

Here's How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today ↗

January 31, 2023

Via Benzinga

What 8 Analyst Ratings Have To Say About Edwards Lifesciences ↗

January 30, 2023

Via Benzinga

A Preview Of Edwards Lifesciences's Earnings ↗

January 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗

February 06, 2023

Via Benzinga

Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023 ↗

February 01, 2023

Via Benzinga

2 Top Dividend Growth Stocks to Buy in February ↗

February 01, 2023

They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.

Via The Motley Fool

Expert Ratings for Edwards Lifesciences ↗

November 28, 2022

Via Benzinga

15 Analysts Have This to Say About Edwards Lifesciences ↗

November 28, 2022

Via Benzinga

Earnings Scheduled For January 31, 2023 ↗

January 31, 2023

Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday ↗

January 30, 2023

Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market...

Via Benzinga

2 Smartest Tech Stocks to Buy in 2022 and Beyond ↗

December 20, 2022

The tech space is still bursting with opportunities for long-term investors.

Via The Motley Fool

Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators' ↗

December 16, 2022

Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.

Via Benzinga

JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday ↗

December 06, 2022

Via Benzinga

Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands ↗

November 28, 2022

Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗

December 06, 2022

Via Benzinga

S&P 500 Component DexCom Set For Further Price, Earnings Growth

November 13, 2022

Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.

Via MarketBeat

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022 ↗

December 02, 2022

Via Benzinga

Edwards Life Sciences Stock Disaster Could Be Your Bounty

November 07, 2022

Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.

Via MarketBeat

Topics Death

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com